Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncolytics Biotech has reported positive interim results from a UK Phase Ia/Ib combination Reolysin and radiation clinical trial for patients with advanced or metastatic cancers.
Subscribe to our email newsletter
To date, 22 patients have been treated with 15 having completed the study. Five patients withdrew from the study, and two patients are still on study. A total of 11 patients in the Ia portion of the trial received two intratumoural treatments of Reolysin at dosages of 1×10(8), 1×1(9), or 1×10(10) TCID(50) with a constant localized radiation dose of 20Gy given in five fractions. Of these 11 patients, three patients (oesophageal, squamous skin carcinoma and squamous cell scalp) experienced significant partial responses.
One month following treatment, the oesophageal patient experienced a 28.5% reduction in the target tumor, with stable disease noted in four, non-treated tumors. At two and three months, the target tumor had shrunk 64%, with stable disease continuing in the four non-treated tumors, including a 15% volume reduction in non-treated mediastinal disease that was maintained for more than six months. The squamous skin cancer patient experienced a 50% reduction in the target tumor, as well as stable disease in two, non-treated tumors at one, two and three months post treatment.
Dr Brad Thompson, president and CEO, said: “We are very pleased with the results of this trial to date and continue to evaluate the data and look forward to announcing final results.”